Lawhead R A, Clark D G, Smith D H, Pierce V K, Lewis J L
Department of Gynecology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Gynecol Oncol. 1989 Jun;33(3):279-82. doi: 10.1016/0090-8258(89)90512-x.
From January 1, 1972 to December 31, 1981, sixty-five patients underwent pelvic exenteration as treatment for recurrent or persistent gynecologic malignancy at Memorial Sloan-Kettering Cancer Center. Cervical carcinoma was the disease most commonly treated by exenteration. The operative mortality of 9.2% represents an improvement over previous reports from this institution. After routine use of prophylactic minidose heparin, no cases of thrombophlebitis or pulmonary embolus occurred postoperatively. A 5-year survival rate of 23% warrants continued use of exenteration in carefully selected patients. The significant mortality and morbidity associated with pelvic exenteration preclude its use as a palliative procedure.
1972年1月1日至1981年12月31日期间，65例患者在纪念斯隆-凯特琳癌症中心接受盆腔脏器清除术，以治疗复发性或持续性妇科恶性肿瘤。宫颈癌是最常通过盆腔脏器清除术治疗的疾病。9.2%的手术死亡率较该机构之前的报告有所改善。在常规使用预防性小剂量肝素后，术后未发生血栓性静脉炎或肺栓塞病例。23%的5年生存率表明，在精心挑选的患者中继续使用盆腔脏器清除术是合理的。盆腔脏器清除术相关的显著死亡率和发病率使其不能用作姑息性手术。
